Join Growin Stock Community!

威力德生醫7713.TW Overview

TW StockBiotech. & Medical
(No presentation for 7713)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

威力德生醫（7713）Overall Performance

威力德生醫（7713）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

威力德生醫（7713） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

威力德生醫（7713）Key Information

威力德生醫（7713）Profile

WeLeader Biomedical Co. Ltd. engages in the production and sale of medical diagnostic equipment and materials. It provides serum biochemistry integration platform, clinical care and medical information integration systems. The company was founded on April 28, 2003 and is headquartered in Kaohsiung City, Taiwan.

威力德生醫（7713）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
16.74
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
32.48%
Net Margin
17.99%
Revenue Growth (YoY)
-12.73%
Profit Growth (YoY)
-11.18%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
16.74
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
32.48%
Net Margin
17.99%
Revenue Growth (YoY)
-12.73%
Profit Growth (YoY)
-11.18%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

7713

威力德生醫

70.30D

0.43%

(0.00)

  • When is 7713's latest earnings report released?

    The most recent financial report for 威力德生醫 (7713) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 7713's short-term business performance and financial health. For the latest updates on 7713's earnings releases, visit this page regularly.

  • Where does 7713 fall in the P/E River chart?

    According to historical valuation range analysis, 威力德生醫 (7713)'s current price-to-earnings (P/E) ratio is 14.61, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 7713?

    According to the latest financial report, 威力德生醫 (7713) reported an Operating Profit of 74.83M with an Operating Margin of 25.29% this period, representing a growth of 35.23% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 7713's revenue growth?

    In the latest financial report, 威力德生醫 (7713) announced revenue of 295.89M, with a Year-Over-Year growth rate of 15.79%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 7713 have?

    At the end of the period, 威力德生醫 (7713) held Total Cash and Cash Equivalents of 207.57M, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 7713 go with three margins increasing?

    In the latest report, 威力德生醫 (7713) achieved the “three margins increasing” benchmark, with a gross margin of 34.57%%, operating margin of 25.29%%, and net margin of 20.22%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 7713's profit trajectory and future growth potential.

  • Is 7713's EPS continuing to grow?

    According to the past four quarterly reports, 威力德生醫 (7713)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.32. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.